Intellia Therapeutics News - September 2026

Intellia's CRISPR Therapy Lonvo-z Granted FDA Priority Review for Hereditary Angioedema

Intellia Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for lonvoguran ziclumeran...

Intellia Gains FDA Priority Review for World’s First In Vivo CRISPR Therapy

Intellia Therapeutics announced the FDA accepted its Biologics License Application (BLA) for lonvoguran ziclumeran (lonvo-z). The agency granted Priority...